Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Third generation dendritic cell vaccines for tumor immunotherapy.
Eur. J. Cell Biol. 91, 53-58 (2012)
This review summarizes our studies of the past several years on the development of third generation dendritic cell (DC) vaccines. These developments have implemented two major innovations in DC preparation: first, young DCs are prepared within 3days and, second, the DCs are matured with the help of Toll-like receptor agonists, imbuing them with the capacity to produce bioactive IL-12 (p70). Based on phenotype, chemokine-directed migration, facility to process and present antigens, and stimulatory capacity to polarize Th1 responses in CD4(+) T cells, induce antigen-specific CD8(+) CTL and activate natural killer cells, these young mDCs display all the important properties needed for initiating good antitumor responses in a vaccine setting.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Dendritic cells; Young dendritic cells; Dendritic cell-based vaccines; Antitumor response; Memory effector cytotoxic T lymphocytes; Dendritic cell maturation; Th1-polarization
ISSN (print) / ISBN
0171-9335
e-ISSN
1618-1298
Journal
European Journal of Cell Biology
Quellenangaben
Volume: 91,
Issue: 1,
Pages: 53-58
Publisher
Elsevier
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Molecular Immunology (IMI)